San Diego-based Viking Therapeutics marked by itself as a serious competitor during the weight loss drug market in February soon after revealing promising info from the mid-stage trial of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when presented as a weekly injection As well as in March the compan